Navigation Links
Merriman Capital to Host Pressure BioSciences, Inc. Investor Call at 4:30 p.m. EST on Thursday, December 12, 2013
Date:12/11/2013

SOUTH EASTON, Mass., Dec. 11, 2013 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced that Merriman Capital, Inc. ("Merriman"), a wholly owned subsidiary of Merriman Holdings, Inc. (OTCQX: MERR), will host an investor call for PBI on Thursday, December 12, 2013 at 4:30 p.m. EST. Pressure BioSciences CEO Richard T. Schumacher and Board Chairman Jeffrey N. Peterson will provide an update on the Company, including a review of the achievements of 2013 and stated goals for 2014, via a webcast with an accompanying PowerPoint presentation.

All investors and interested parties are welcome to join the conference call and webcast. A question and answer session will follow the opening remarks and presentation.  Mr. Schumacher, Mr. Peterson, and board members Mr. Vito Mangiardi, Mr. Kevin Pollack, and Dr. Mickey Urdea will be available during the Q&A session.

Conference Call, Webcast and Presentation Information

Date:  Thursday, December 12, 2013
Time:  4:30 PM Eastern Standard Time (EST)

To listen to this teleconference via telephone (whether or not watching the webcast):
Dial-in: (800) 875-3456 (U.S.); (800) 648-0973 (Canada); (302) 607-2001 (International)
Passcode: VS87265      Conference ID: 865561

To view the webcast, use the following conference link (NOTE: you must use the call-in number above for the audio portion of the webcast):    http://www.join.me/pbio.investormeeting.M1.

The PBIO presentation will be available for viewing and downloading as of 10 a.m. EST, Thursday, December 12, 2013 on the Company's website:    http://www.pressurebiosciences.com.

For those unable to participate in the live teleconference, a replay will be available approximately one hour after the call and will be accessible through the Company's website for 30 days. 

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) is focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology ("PCT").  PCT is a patented, enabling technology platform with multiple applications in the estimated $6 billion life sciences sample preparation market.  PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions.  PBI currently focuses its efforts on the development and sale of PCT-enhanced sample preparation systems (instruments and consumables) for mass spectrometry, biomarker discovery, bio-therapeutics characterization, vaccine development, soil and plant biology, forensics, histology, and counter-bioterror applications.

About Merriman Capital, Inc.

Merriman Capital, Inc. is a full service investment bank and Broker-Dealer that facilitates efficient capital formation through a proprietary digital network, as well as Capital Markets Advisory and comprehensive Corporate Brokerage services for public and private companies. The firm also provides equity and options execution services for sophisticated investors and differentiated research for high growth companies. Merriman Capital, Inc. is a wholly owned brokerage subsidiary of Merriman Holdings, Inc. (OTCQX: MERR) and is a leading advisory firm for publicly traded, high-growth companies.

Merriman Capital, Inc. is a registered broker-dealer and member of The Financial Industry Regulatory Authority (FINRA) http://www.finra.org/ and the Securities Investor Protection Corporation (SIPC) http://www.sipc.org/.

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2012, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

           For more information about PBI and this press release, please click on the following website link: 
                                                 Please visit us on: Facebook, LinkedIn, and Twitter.
                                                             http://www.pressurebiosciences.com

Investor Contacts:
Richard T. Schumacher, President & CEO, Pressure BioSciences, Inc.                     (508) 230-1828 (T)
Douglas Rogers, Managing Director, Merriman Capital, Inc.                                      (415) 248-5612 (T)


'/>"/>
SOURCE Pressure BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Economic Growth Continues In 2014; Manufacturing Growth Expected in 2014; Revenue to Increase 4.4%; Capital Expenditures to Increase 8.0%; Capacity Utilization Currently at 80.3%; Non-Manufacturing Growth Projected in 2014; Revenue to Increase 3.6%;
2. Healthcare Companies Report Stock Price Updates, and Medical System Integration - Research Report on Johnson & Johnson, Geron, Ligand Pharmaceuticals, Masimo, and Capital Senior Living
3. Creekridge Capital Grows Healthcare Sales Team
4. Exagen Diagnostics, Inc. and Capital Royalty Close Financing Transaction
5. Sector Leaders Briefing & Capital Raise News: Muscle Warfare, Baidu, Herblife, Gilead Sciences and ARIAD
6. American Capital Commits $391 Million in the Combination of Cambridge Major Laboratories and AAIPharma Services
7. TVM Capital MENA Announces Affiliation with Bostons Spaulding Rehabilitation Network
8. Sarissa Capital Issues Open Letter Regarding Astex Pharmaceuticals
9. Immune Pharmaceuticals Announces Focus on Capital Raising and Primary Listing in The United States
10. Creekridge Capital Launches Vendor Sales Training Program
11. BioSpecifics Technologies Corp. to Present at the Aegis Capital 2013 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... and Markets has announced the addition of the "Vital Signs Monitoring ... Industry Forecast, 2014-2022" report to their offering. ... Vital signs monitoring market size was worth $3,694 ... growing at a CAGR of 5.8% from 2016 to 2022. ... in global vital signs monitoring devices industry. The blood pressure monitoring devices ...
(Date:1/18/2017)... SAN JOSE, Calif. , Jan. 18, 2017  Adaptive ... machines, announced today a new partnership with Hyatt Place ... guests by providing ASTI LectroFan sleep therapy machines in ... "Obviously one of the most important parts of having ... Wicks , general manager of Hyatt Place Nashville/Downtown. "We,re ...
(Date:1/18/2017)... LITTLE FALLS, N.J. , Jan. 18, 2017 /PRNewswire/ ... RGIN ), a biotechnology company specializing in the development ... health of damaged tissues and organs, recently reported the ... key milestones for 2017. As the Company ... 2016 has been a year of substantial accomplishments. The ...
Breaking Medicine Technology:
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... in a medical capacity this year. Drs. Alexander Paziotopoulos, Andrew Petersen and Trish ... a condensed version of the clinic’s leading recovery program. , “We know ...
(Date:1/19/2017)... ... 19, 2017 , ... Bio-Optronics Inc. is proud to announce ... designed to seamlessly integrate and streamline the way researchers prepare and conduct patient ... usability and improving efficiency significantly for users – a first in the CTMS ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... panel system. , The Tranquility privacy panel system was designed to deliver ... Tranquility panels help reduce noise and provide the visual privacy required to maintain ...
(Date:1/19/2017)... ... January 19, 2017 , ... Rountree ... planning services to communities throughout eastern Georgia, is embarking on a charity effort ... Heart disease kills more Americans every year than anything else, yet risk factors ...
(Date:1/19/2017)... , ... January 19, 2017 , ... Attorney Robert ... fifth consecutive year donated money to the Triumph Over Kid Cancer foundation. Each year, ... one of those children. James saw firsthand the effect of the critical funding gap ...
Breaking Medicine News(10 mins):